Journal: Acta Orthopaedica

Article Title: The use of antibiotic-loaded bone cement and systemic antibiotic prophylactic use in 2,971,357 primary total knee arthroplasties from 2010 to 2020: an international register-based observational study among countries in Africa, Europe, North America, and Oceania

doi: 10.2340/17453674.2023.17737

Figure Lengend Snippet: Type of SAP used as reported by 9 of 16 participating registries: DKR, FAR, JointCare, KP, NZJR, NAR, PABZ, RAR, and SAR (n = 530,495 TKAs)

Article Snippet: Palacos R+G (Heraeus Medical, Wehrheim, Germany) was the most common (62%) ALBC type reported followed by Refobacin Bone Cement R (Zimmer Biomet, Warsaw, IN, USA) (18%), Simplex with Tobramycin (Stryker, Kalamazoo, MI, USA) (5%), CMW 2 G (DePuy, Warsaw, IN, USA) (4%), Palacos MV+G (Heraeus Medical) (3%), and SmartSet GHV (DePuy) (3%).

Techniques:

Journal:

Article Title: Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary Tobramycin

doi: 10.1007/s11999-008-0199-2

Figure Lengend Snippet: A comparison of Nebcin (Lilly, Indianapolis, IN) on the left and generic tobramycin on the right illustrates the difference in volume for the same 1.2 g dose. The generic tobramycin volume is approximately 3.5 times greater than the volume of the proprietary tobramycin.

Article Snippet: Several premixed AL-PMMA products including one containing 1 g tobramycin (Simplex P with tobramycin; Stryker Orthopaedics, Mahwah, NJ) have been approved by the FDA for use in revision arthroplasty fixation.

Techniques: Comparison

Journal:

Article Title: Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary Tobramycin

doi: 10.1007/s11999-008-0199-2

Figure Lengend Snippet: Cumulative tobramycin release as a function of time showing the release pattern of tobramycin from antibiotic-loaded polymethylmethacrylate. Beads made with generic tobramycin elute more than twice as fast as beads made with proprietary tobramycin.

Article Snippet: Several premixed AL-PMMA products including one containing 1 g tobramycin (Simplex P with tobramycin; Stryker Orthopaedics, Mahwah, NJ) have been approved by the FDA for use in revision arthroplasty fixation.

Techniques:

Journal:

Article Title: Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary Tobramycin

doi: 10.1007/s11999-008-0199-2

Figure Lengend Snippet: Tobramycin release ratio showing the ratio of released tobramycin mass (Mt) at time (t) over the total tobramycin available for release (Minf) as a function of time. The ratio for the generic bead set is similar to the proprietary bread set suggesting the mechanisms of release are similar for both.

Article Snippet: Several premixed AL-PMMA products including one containing 1 g tobramycin (Simplex P with tobramycin; Stryker Orthopaedics, Mahwah, NJ) have been approved by the FDA for use in revision arthroplasty fixation.

Techniques:

Journal:

Article Title: Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary Tobramycin

doi: 10.1007/s11999-008-0199-2

Figure Lengend Snippet: Log of tobramycin release ratio as a function of the log of time. The slope of this log-log plot is the coefficient of diffusion (n) used in Fig. 5. The slope is similar for the two bead sets and it decreases with time.

Article Snippet: Several premixed AL-PMMA products including one containing 1 g tobramycin (Simplex P with tobramycin; Stryker Orthopaedics, Mahwah, NJ) have been approved by the FDA for use in revision arthroplasty fixation.

Techniques: Diffusion-based Assay

Journal:

Article Title: Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary Tobramycin

doi: 10.1007/s11999-008-0199-2

Figure Lengend Snippet: The coefficient of diffusion (n) from Mt = ktn as a function of time. The coefficient of diffusion (n) indicates the dominant release mechanism. The plotted values are a 5-day moving average not including Day 1 [2]. When n = 1, release is dominated by dissolution of the particulate tobramycin directly into the eluent (zero-order release, constant rate). When n = 0.5, release is dominated by diffusion of tobramycin from deep in the pore system (first-order release, rate is dependent on the amount of remaining tobramycin). Between 0.5 and 1, the release mechanism is termed anomalous diffusion, a combination of dissolution and diffusion. During the first 9 days, dissolution appeared more dominant in the generic bead set than the proprietary bead set. Subsequently, the release mechanisms appear similar as anomalous diffusion transitions to diffusion in both.

Article Snippet: Several premixed AL-PMMA products including one containing 1 g tobramycin (Simplex P with tobramycin; Stryker Orthopaedics, Mahwah, NJ) have been approved by the FDA for use in revision arthroplasty fixation.

Techniques: Diffusion-based Assay, Dissolution

Journal: Trauma Case Reports

Article Title: Femoral component retention in Rorabeck type III periprosthetic knee fracture with plating fixation and bone cement augmentation. A new surgical technique and four cases reported

doi: 10.1016/j.tcr.2024.101084

Figure Lengend Snippet: View of the loose prosthesis and bone defect after loose bone fragments were removed. A 4.5/5 mm LCP proximal tibial T plate (DpS USA) was placed to fix the lateral epicondyle fragment, and drilling and placing the epiphyseal screws before cementing to check metal-work conflict (a), filling. The defect was then filled with the PMMA Syringe (b) the distal LS was placed again before packing the PMMA (c). The redundant cement was removed, and the final aspect after the cement was set is shown (d).

Article Snippet: After vacuum mixing the Polymethyl methacrylate (PMMA) (Tobramicine Simplex® Stryker) cement for the standardized times recommended by the manufacturer, the anterolateral defect was filled with the syringe and then packed.

Techniques: